Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical. Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no, or limited, treatment options. As part of the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!